Ocean Genomics, Inc.
Ocean Genomics, Inc., founded in 2018, is a biotechnology company based in Pittsburgh, PA, specializing in gene expression and transcriptomics. The company utilizes AI models and a vast gene expression database to provide advanced computing platforms for gene expression analysis and biomarker discovery.
Company Overview
Ocean Genomics, Inc. is a biotechnology company founded in 2018, headquartered in Pittsburgh, PA. The company operates with a small team of 10 employees and specializes in gene expression and transcriptomics. It describes itself as 'Gene Expression Experts' and focuses on providing advanced computing platforms for gene expression analysis, biomarker discovery, and target identification.
Services Offered
Ocean Genomics offers a range of services that include integrated programs for gene expression analysis, from single experiment analyses to multi-milestone projects. The company utilizes AI models and a comprehensive gene expression database to deliver insights for drug discovery and development across various therapeutic areas. Their platforms, TxomeAI® and DiscoverAI™, automatically integrate transcriptomics with other data sources to create actionable models.
Technology and Platforms
The Intelligent Transcriptome platform, developed by Ocean Genomics, integrates gene expression, clinical, and multi-omic data with advanced AI algorithms. This platform has been validated by experts in transcriptome analysis and machine learning. The company also maintains DeepSea™, a vast transcriptome database that supports discovery and analysis, and has developed numerous RNA-seq software applications that are widely used in the industry.
Research and Collaborations
Ocean Genomics partners with leading drug developers to provide insights that facilitate data-driven decisions. The company has presented research at significant conferences, including a poster at ASCO 2023 in collaboration with Yale Cancer Center. Their work includes identifying molecular predictors in cancer treatment and developing expression-based Immuno-Oncology biomarkers that enhance the validity of mutational-burden biomarkers.
Funding and Investments
The company has received strategic investment from Accenture to enhance its AI-driven drug discovery initiatives and the development of personalized medicines. Additionally, Ocean Genomics was awarded a grant by the BIRD Foundation to advance a multi-omic software method, further demonstrating its commitment to innovation in the biotechnology sector.